A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis

Roberto Furlan, Asli Kurne, Alessandra Bergami, Elena Brambilla, Raffaella Maucci, Laura Gasparini, Erica Butti, Giancarlo Comi, Ennio Ongini, Gianvito Martino

Research output: Contribution to journalArticlepeer-review

Abstract

Nitric oxide (NO)-releasing non-steroidal anti-inflammatory drugs (NSAIDs) have been reported to have a safer profile and additional anti-inflammatory and immuno-modulatory properties compared to parent compounds. Preventive treatment of experimental autoimmune encephalomyelitis (EAE)-induced in C57BL/6 mice by immunization with myelin oligodendrocyte glycoprotein (MOG) peptide 35-55-with the NO-releasing derivative of flurbiprofen HCT1026 delayed disease onset and significantly decreased disease severity. HCT1026 treatment was associated to (i) decreased mRNA levels of pro-inflammatory cytokines, caspase-1, and iNOS in blood cells; (ii) decreased ability of encephalitogenic T cells to proliferate; (iii) reduced number of central nervous system (CNS)-infiltrating T cells; (iv) decreased axonal loss and demyelination; (v) increased CD4+ CD69 - CD25+ regulatory T cells in the spleen.

Original languageEnglish
Pages (from-to)10-19
Number of pages10
JournalJournal of Neuroimmunology
Volume150
Issue number1-2
DOIs
Publication statusPublished - May 2004

Keywords

  • Caspase-1
  • EAE
  • IFN-γ
  • IL-10k/o
  • Nitric oxide
  • NSAID

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Fingerprint Dive into the research topics of 'A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis'. Together they form a unique fingerprint.

Cite this